Announcements Trials
Browse Landscape

Phase

Phase NA 4Phase 3 3Phase 1 2Phase 2 1

Status

Completed 6Unknown 2Recruiting 2Withdrawn 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Genitourinary 1

Conditions

Neoplasms 1Castration Sensitive Prostate Cancer 1

Interventions

Cyclophosphamide 118pembrolizumab 104Specimen Handling 104Magnetic Resonance Spectroscopy 94fludarabine 92Biopsy 77Injections 53Nivolumab 43Bevacizumab 41Fluorouracil 38venetoclax 37Cisplatin 36Paclitaxel 35Carboplatin 35Cetuximab 34Radiotherapy 31Oxaliplatin 30fludarabine phosphate 29Leucovorin 28Gemcitabine 28Drug Therapy 25Ipilimumab 23Immunotherapy, Adoptive 23Azacitidine 23Radiation 21Irinotecan 21Temozolomide 20Doxorubicin 20tislelizumab 19atezolizumab 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Recruiting × Curcumin × Clear all
NCT06626230 2026-05-18

Safety of Anal Curcumin

Emory University

Phase 1 Recruiting
48 enrolled
Tumor-Agnostic

Neoplasms

NCT06044025 2026-01-15

A Feasibility Study Evaluating a Role for Maintenance Therapy in Patients With Biochemically Progressive Castration Sensitive Prostate Cancer on Intermittent Androgen Deprivation Therapy

University of Arkansas

Phase 1 Recruiting
34 enrolled
Genitourinary

Castration Sensitive Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡